Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously

Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Haitao Huang, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Jingxin Li, Wei Chen, Fengcai Zhu
doi: https://doi.org/10.1101/2022.07.26.22278072
Lairun Jin
1School of Public Health, Southeast University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Tang
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shipo Wu
3Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiling Guo
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihua Hou
3Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoqin Chen
4Donghai County Center for Disease Control and Prevention, Donghai, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Zhu
5Cansino Biologics Inc., Tianjin, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinbo Gou
5Cansino Biologics Inc., Tianjin, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haitao Huang
5Cansino Biologics Inc., Tianjin, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Zhong
4Donghai County Center for Disease Control and Prevention, Donghai, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongxing Pan
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lunbiao Cui
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin chen
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Xia
6School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jialu Feng
6School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue Wang
5Cansino Biologics Inc., Tianjin, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Zhao
5Cansino Biologics Inc., Tianjin, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XiaoYu Xu
7Vazyme Biotech Co., Ltd, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhuopei Li
6School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyin Zhang
1School of Public Health, Southeast University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingxin Li
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
6School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, P.R China
8Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jszfc@vip.sina.com jingxin42102209@126.com cw0226@foxmail.com
Wei Chen
3Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jszfc@vip.sina.com jingxin42102209@126.com cw0226@foxmail.com
Fengcai Zhu
1School of Public Health, Southeast University, Nanjing, Jiangsu Province, P.R China
2National Health Commission (NHC) Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Jiangsu Province, P.R China
6School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, P.R China
8Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, P.R China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jszfc@vip.sina.com jingxin42102209@126.com cw0226@foxmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose CoronaVac (an inactivated SARS-CoV-2 vaccine, by Sinovac) previously, has been reported to be safe and highly immunogenic within 28 days post-boosting. However, antibody persistence and safety up to 6 months of this regimen are not been reported yet.

Methods This is a randomized, open label, single-center trial on safety and immunogenicity of heterologous boost immunization with an orally administered aerosolised Ad5-nCoV vs. homologous boost immunization with CoronaVac after two-dose priming with CoronaVac in Chinese adults aged 18 years and older (NCT05043259). We followed the participants in this trial, including 140 in the low-dose aerosolised Ad5-nCoV group, 139 in the high-dose aerosolised Ad5-nCoV group, and 140 in the CoronaVac group for 6 months. Neutralising antibodies (NAbs) against live wild-type SARS-CoV-2 virus and omicron variant, and receptor-binding domain (RBD)-specific IgG antibodies were detected in serum samples collected at 28 days, 3 months, and 6 months after the booster dose. Serious adverse events (SAEs) were documented till month 6.

Results The low-dose and high-dose heterologous boost immunisation groups had NAb GMTs against live wild-type SARS-CoV-2 of 1937.3 [95% CI 1466.9, 2558.4] and 1350.8 [95% CI 952.6, 1915.3], which were 26.4 folds and 18.4 folds higher than that the CoronaVac group did (73.5 [95% CI 52.3, 103.3]) at 28 days. The low-dose and high-dose heterologous boost immunisation groups had NAb GMTs against live wild-type SARS-CoV-2 of 530.1 (95% CI 412.5, 681.1) and 457.6 (95%CI 349.4, 599.2), which were 26.0 folds and 22.4 folds higher than that the CoronaVac group did (20.4 [95%CI 14.3, 29.1]) at 3 months, respectively. At 6 months, the low-dose and high-dose heterologous booster groups had NAb GMTs against live wild-type SARS-CoV-2 of 312.9 (95% CI 237.7, 411.8) and 251.1 (95% CI 178.2, 354.0), which were 30.1 folds and 24.1 folds higher than the CoronaVac group did (10.4 [95% CI 7.8, 14.0]), respectively. Additionally, the low-dose and high-dose heterologous booster groups had NAb GMTs against live omicron variant of 52.0 (95% CI 37.2, 72.6) and 23.1 (95% CI 15.7, 33.9) at 28 days, 27.9 (95% CI 18.8, 41.3) and 23.3 (95% CI 16.2, 33.3) at 3 months, 16.0 (95% CI 10.9, 23.5) and 12.0 (95% CI 8.5, 16.8) at 6 months, respectively. However, nearly all participants had no detectable NAbs for omicron variant in the CoronaVac group at either 28 days, 3 months, or 6 months. No vaccine-related SAEs were observed.

Conclusions These data suggested that heterologous aerosolised Ad5-nCoV following two-dose CoronaVac priming was safe and persistently more immunogenic than three-dose CoronaVac, although immune responses waned over time.

Competing Interest Statement

T.Z., J.G., H.H., X.W., and Q.Z. are employees of CanSino Biologics. All other authors declare no competing interests.

Clinical Trial

NCT05043259

Funding Statement

This work was funded by National Natural Science Foundation of China (grant number: 82173584), Jiangsu Provincial Science Fund for Distinguished Young Scholars (grant number: BK20220064) and Jiangsu Provincial key project of science and technology plan (grant number: BE2021738).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by Research Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention, and was conducted following the principles of the Declaration of Helsinki, ICH Good Clinical Practice guidelines and local guidelines.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The results supporting the findings in this study are available upon request from the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 28, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Haitao Huang, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Jingxin Li, Wei Chen, Fengcai Zhu
medRxiv 2022.07.26.22278072; doi: https://doi.org/10.1101/2022.07.26.22278072
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Haitao Huang, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Jingxin Li, Wei Chen, Fengcai Zhu
medRxiv 2022.07.26.22278072; doi: https://doi.org/10.1101/2022.07.26.22278072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)